Glecaprevir/pibrentasvir (G/P) is well-tolerated and efficacious for patients with chronic hepatitis C virus (HCV) genotype 3 (GT3) infection, regardless of cirrhosis status or prior treatment experience. This according to an integrated phase 2/3 analysis in which data were pooled from 5 phase 2 or 3 trials that evaluated 8-, 12-, and 16-week G/P in patients with chronic HCV GT3 infection. Safety and sustained virologic response 12 weeks (SVR12) post-treatment were assessed. Among the details:

• The analysis included 693 patients with GT3 infection.
• SVR12 was achieved by 95% of treatment-naïve patients without cirrhosis receiving 8-week and 12-week G/P.
• Treatment-experienced, non-cirrhotic patients had SVR12 rates of 90% and 95% with 12- and 16-week G/P, respectively.
• 94% of treatment-experienced patients with cirrhosis treated for 16 weeks achieved SVR12.
• No serious adverse events were attributed to G/P.